Imaging agent developer ImaginAb is touting interim results from a phase II clinical trial of its IAB2M imaging agent for managing prostate cancer. {read more here}

A new scan may make it easier for doctors to accurately diagnose Alzheimer’s disease (AD). The results from the Phase III trial of florbetaben F18 injection, known by the trade name Neuraceq, were published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The injection material is a radiopharmaceutical that is used in imaging to “estimate the density of neuritic beta-amyloid plaques in the brains of adult patients with cognitive impairment.” The study was completed at the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Ohio. The lead researcher was Sabri Osama, MD, PhD, of the University of Leipzig, Germany. {read more here}

PET/MRI can provide high diagnostic performance for restaging gynecological cancer patients compared with FDG-PET/CT, with only slightly longer scan time and “markedly reduced” radiation exposure, according to a German study published online August 19 in the European Journal of Radiology. {read more here}

A recent study has highlighted the ability of prostate-specific membrane antigen (PSMA) PET imaging to detect fast-growing primary prostate cancer and could prove significant in the care of patients with suspected prostate cancer that had not been confirmed by biopsy. {read more here}